Assuta's innovation arm launched a program that equips startup companies join the health market

RISE, Assuta's innovation arm launched with US in collaboration with University City Science Center from Philadelphia - a program that equips startup companies to successfully break into the global health market. 101 companies applied to participate in the program, all with an emphasis on digital health solutions, computational technology, artificial intelligence and big data, from which the six most promising companies that qualified for the program were selected.
Thanks to the partnership with the University City Science Center, which has accumulated 50 years of experience in introducing overseas technologies to the market, program participants will gain direct access to hospitals, insurers and academic centers in the Philadelphia  including Pennsylvania State and Princeton, as well as to the Angel Capital Association.
Dr. Michal Gindi, Head of the Innovation Division at Assuta - RISE said: "The program is part of a broad activity that we are promoting to encourage Assuta's relationship with industry and academia in order to be leaders at the forefront of science and in the development of medical technologies, designed to improve the care we provide to patients."
The companies participating in the program are:
IdentifAi offers the first non-invasive fetal DNA test. The technology enables full genetic sequencing of the fetus, through a simple blood test taken from the pregnant woman, which enables accurate identification of genetic disorders in the fetus at an early stage of pregnancy. Other existing solutions in the field are invasive, late and have a certain risk (such as amniocentesis and placental cysts), or are very limited to the detection of a small part of genetic disorders (such as the current NIPT test). IdentifAI's technology is based on long academic research, and it has shown excellent results in clinical research on dozens of cases. The company was founded in 2021 by Oren Tadmor (CEO), Prof. Noam Shomron (CSO) and Dr. Tom Rabinovitch (CTO). The company operates from its offices in Ramat Hayal, and employs 7 people. The company held a pre-seed round in which $1.2M was raised from private investors and another $1.2M from the Innovation Authority and is currently in the middle of a seed round (part of which has already closed).
Epilog develops artificial intelligence-based tools that will be an innovative environment for managing complex challenges in the later stages of life. The company aims to help people make quality-of-life-oriented decisions, with an emphasis on medical decisions. At the beginning of next year, Epilog is expected to begin a clinical study in the United States, as well as hold an initial pilot in collaboration with an international health insurance company, in which thousands of users, who are the target audience for the company's products, will participate. Founded in 2022, by Tal Shafesa Hayman, (CEO) Ofir Shaoman, (CPO) Or Bar-Tal (CTO), Prof. Dan Arieli (Chief Behavioral Officer) and Dr. Roni Tzbar, (Chief Medical Officer) and recruited Sabev Pera -lime.
AccuLine develops CORA - an accurate, fast and easy-to-use test system for the early detection of coronary artery disease in the heart. It assesses the patient's risk of having significant coronary artery disease through advanced analysis and identification of two markers in the electrical activity of the heart and yet while lowering the costs associated with the diagnosis and treatment of vascular and heart diseases. The company was founded in 2022 by Moshe Barel (CEO), Prof. Aharon Primerman (Medical Director), Prof. Shai Ravzan (Scientific Director), and Benny Shani (Chief Technologist). It operates from its offices in Modi'in Ilit and employs two additional employees. The company received a grant from the Innovation Authority as part of an incubator program, and also raised funds from the EHV Fund, Maccabi Health Services and private investors.
Datability develops the first information search platform of its kind in the world, developed by doctors who make decisions based on imaging tests and for them. The innovative technology is patent protected, allows patients to be described in a compact and comparable way, and provides the doctor with a search engine that refers to the patient as a whole (images, records, laboratory results) ) when Eilat. This allows the doctor to dramatically reduce the time required for diagnosis, the number of unnecessary tests that the patient is required to perform, and enable better quality treatment while harnessing the wisdom of the masses. The company was founded in 2021 by Moti Moravia (CTO) and Dr. Maor Fried (CEO It operates from its offices in Tel Aviv and employs six people. The company held a pre-seed round led by TechAviv
Senseera has developed an innovative liquid biopsy test for the monitoring and diagnosis of a large variety of diseases with a single blood test. The cells in our body go through a constant turnover, cells die and new cells are created. When a cell dies, the DNA and proteins spill out of the cell into the bloodstream. The Sensira test extracts information from these substances in the blood and deciphers the state of the cells. When a disease develops in our body, even at the very beginning, cells from the diseased organ change and die. Sensira's test can very sensitively detect these changes and by means of a sophisticated algorithm to monitor the health status and diagnose diseases even in early stages, thus enabling treatment to be started earlier and improving the efficiency of treatment. The company was founded in 2014 by Prof. Nir Friedman (Chairman), Dr. Ronan Sade (Vice President of Engineering), Dr. Genia Gutin (Vice President of Technology) and Israa Shekariya (Vice President of Research and Development). The company operates from Jerusalem and employs 11 people.
Wotch introduces for the first time a platform that serves as an autonomous assistant for doctors and patients. Wotch's product is an interface that receives instructions from the doctor and performs medical operations under the doctor's supervision, in a manner similar to the operation of a certified physician's assistant. At the same time, the interface serves for the patient as an autonomous treatment manager who navigates, monitors and provides him with certainty and accurate information regarding his condition and place in his personal treatment process. Wotch is planned to carry out a pilot with Maccabi Health Services in the first quarter of 2023. The company was founded in 2021 by Dr. Enav Nof Sade (CEO and Yoni Dagan (CTO), operates from Israel and employs 10 people. The company raised a seed of approximately $3M from investors Details.